TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$155 Million

Personalis, Inc.

Initial Public Offering

Bookrunner, June 2019

Personalis, Inc.
Personalis is a cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The company designed their NeXT Platform to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system. The company is also developing a complementary liquid biopsy assay that analyzes all human genes.